A NEW nasal spray that trap & neutralize not only SARS-CoV-2, Influenza, RSV, Adeno & many other viruses & bacteria that are inhaled into the nose, immobilizing them until they die. The substance is >99.9% effective & contains no drugs 1/
The FDA approved substance in the spray is known as the Pathogen Capture and Neutralizing Spray (PCANS), & contains no drugs of any kind.
Instead, the spray forms a gel that lines the inside of the nose. 2/
While this gel doesn't affect the user's breathing, it does trap any viruses or bacteria that are subsequently inhaled into the nose, immobilizing them until they die. 3/
In lab tests, the spray protected mice from a mouse-adapted form of the H1N1 influenza virus, even when that virus was administered at 25 times the lethal dose. 4/
What's more, virus levels in the animals' lungs were reduced by over 99.99% as compared to an untreated control group of mice. The spray was retained in the rodents' noses for up to eight hours, and was effective at blocking infection for at least four hours. 5/
Although PCANS has yet to be tested on humans, it has been used in a 3D-printed model of a human nose, where it captured twice as many microbe-containing droplets as mucus alone. 6/
It blocked and neutralized almost 100% of all viruses and bacteria we tested, including influenza, SARS-CoV-2, RSV, adenovirus, K Pneumonia and more. 7/
And if you suffer from allergies, take note – the researchers believe the spray could one day also be used on a daily basis to trap and neutralize allergens. 8/8
A new study shows that coronavirus spike proteins can trigger mast cell degranulation by binding to cellular receptors and activating the Src/PI3K/AKT signaling pathway, leading to increased calcium levels and mast cell granule release. 1/
The activation and degranulation of mast cells (MCs), triggered by a variety of viruses, are intricately linked to viral pathogenesis. However, the precise mechanism underlying virus-induced MC degranulation remains largely unknown. 2/
In this study, researchers demonstrate the ubiquity of coronavirus-induced MC degranulation and investigate the intracellular signaling pathways that mediate this process. 3/
Tiny RNA molecule may hold the key to treating knee osteoarthritis!
A NEW discovery could pave the way for new breakthroughs in detecting & treating the disease. Researchers identified a circulating microRNA, miR-126-3p, a mechanistic biomarker of osteoarthritis of knee 1/
MiR-126-3p plays a role in reducing blood vessel formation and reducing the severity of knee osteoarthritis, making it not just a signal of disease—but potentially a contributor to it. 2/
Now that scientists are aware of miR-126-3p, they can develop blood tests to detect osteoarthritis of the knee and therapeutics for slowing or even stopping progression. 3/
A new preprint validated earlier findings that genetic factors strongly influence who develops Long COVID, using data from both U.S. (All of Us) and U.K. (Sano GOLD) cohorts with diverse ancestries. 1/
Over 90% of genes identified in the original study were also associated with #LongCOVID in the U.S. population including in Black and Hispanic groups. 2/
These results confirm that combinatorial genetic analysis can uncover more risk genes than traditional Genome-wide association studies (GWAS) and support the continued exploration of drug repurposing candidates for LongCOVID treatment. 3/
A team of researchers has launched a global clinical trial to evaluate two repurposed anti-inflammatory drugs #upadacitinib and #pirfenidone—approved for treating arthritis and lung disease, respectively as potential treatments for #LongCOVID. 1/
he two drugs were selected using artificial intelligence (AI) from over 5,400 proteins linked to LongCOVID, offering a promising shortcut to treatment by targeting 13 shared biological pathways. 2/
Despite the global prevalence of longCOVID, patients report different symptoms & their presentation can be influenced by where they happen to live. 3/
A group from SUNY Buffalo developed a nanoparticle vaccine candidate that displays recombinant H5 and N1 proteins from the highly pathogenic avian influenza H5N1 clade 2.3.4.4b on liposomes. 1/
The widespread transmission of highly pathogenic avian H5N1 influenza, clade 2.3.4.4b, in wild and livestock mammals with isolated human cases has heightened concerns for zoonotic outbreak, necessitating vaccine readiness. 2/
Here, the researchers assess whether recombinant H5 hemagglutinin and N1 neuraminidase proteins can confer protection from disease when antigens are presented as an adjuvanted nanoparticle vaccine. 3/
Children who tested positive for COVID, face significantly higher long-term risks for chronic kidney disease, gastrointestinal disorders, and cardiovascular issues compared to peers who tested negative. 1/
The study, led by the University of Pennsylvania and part of the NIH’s RECOVER initiative, found kidney disease risks increased up to 35%, GI symptoms by up to 28%, and cardiovascular conditions like heart inflammation or arrhythmias by 63%. 2/
Racial differences also emerged with Asian American Pacific Islander children showing slightly higher LongCOVID risk. 3/